CIA
GPCR icon

Concurrent Investment Advisors’s Structure Therapeutics GPCR Stock Holding History

Concurrent Investment Advisors’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$241K Hold
5,000
– – ﹤0.01% 1632
2025
Q4 		$348K Buy
+5,000
New +$204K ﹤0.01% 1312

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Concurrent Investment Advisors's GPCR Position: Q1 2026 in Review

Concurrent Investment Advisors held its Structure Therapeutics (GPCR) position steady in Q1 2026 at 5,000 shares worth $241K. The position accounts for ﹤0.01% of the portfolio, ranked #1632.

Concurrent Investment Advisors first reported a position in GPCR in Q4 2025 and has held it in 2 quarters since. The position peaked at $348K in Q4 2025. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

  • Concurrent Investment Advisors held 5,000 shares of Structure Therapeutics worth $241K as of Q1 2026.
  • Concurrent Investment Advisors left its Structure Therapeutics share count unchanged in Q1 2026.
  • Structure Therapeutics made up ﹤0.01% of Concurrent Investment Advisors's portfolio in Q1 2026, its #1632 holding.
  • Concurrent Investment Advisors first reported a position in Structure Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Concurrent Investment Advisors's Structure Therapeutics position peaked at $348K in Q4 2025.
  • 196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on Concurrent Investment Advisors's 13F filing for Q1 2026, filed 21 Apr 2026.